- Home
- GALT vs FLYX Comparison
GALT vs FLYX Comparison
Compare GALT & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- FLYX
- Stock Information
- Founded
- GALT 2000
- FLYX 2015
- Country
- GALT United States
- FLYX United States
- Employees
- GALT N/A
- FLYX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- FLYX Blank Checks
- Sector
- GALT Health Care
- FLYX Finance
- Exchange
- GALT Nasdaq
- FLYX Nasdaq
- Market Cap
- GALT 147.8M
- FLYX 175.8M
- IPO Year
- GALT N/A
- FLYX N/A
- Fundamental
- Price
- GALT $2.12
- FLYX $2.37
- Analyst Decision
- GALT Strong Buy
- FLYX Hold
- Analyst Count
- GALT 1
- FLYX 1
- Target Price
- GALT $11.00
- FLYX N/A
- AVG Volume (30 Days)
- GALT 549.5K
- FLYX 14.5K
- Earning Date
- GALT 11-13-2024
- FLYX 01-01-0001
- Dividend Yield
- GALT N/A
- FLYX N/A
- EPS Growth
- GALT N/A
- FLYX N/A
- EPS
- GALT N/A
- FLYX N/A
- Revenue
- GALT N/A
- FLYX $311,873,000.00
- Revenue This Year
- GALT N/A
- FLYX $15.91
- Revenue Next Year
- GALT N/A
- FLYX $39.64
- P/E Ratio
- GALT N/A
- FLYX N/A
- Revenue Growth
- GALT N/A
- FLYX N/A
- 52 Week Low
- GALT $1.56
- FLYX $1.79
- 52 Week High
- GALT $4.27
- FLYX $24.21
- Technical
- Relative Strength Index (RSI)
- GALT 39.78
- FLYX 54.00
- Support Level
- GALT $1.80
- FLYX $2.04
- Resistance Level
- GALT $2.36
- FLYX $2.67
- Average True Range (ATR)
- GALT 0.23
- FLYX 0.22
- MACD
- GALT -0.03
- FLYX 0.03
- Stochastic Oscillator
- GALT 26.89
- FLYX 52.22
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 90 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.